Every 10-Q that Predictive Oncology Inc. (POAI) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow POAI and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full POAI filings page.
Axe Compute Inc. reported a sharp increase in quarterly losses driven by its ATH digital-asset strategy and minimal revenue from operations. For the three months ended March 31, 2026, revenue fell to $35,311 from $110,310 a year earlier, mainly due to lower activity in its Drug Discovery Services segment.
The company recorded a $4.3 million loss on digital assets, primarily from fair value declines in Aethir (ATH) tokens, leading to a net loss of $7.7 million versus $2.4 million last year. As of March 31, 2026, Axe Compute held $6.9 million in cash and cash equivalents, $20.2 million of ATH at fair value, and a $15.4 million digital asset receivable tied to locked ATH. Management is focusing on the ATH-based Treasury Strategy and GPU compute services while exploring strategic alternatives for its legacy oncology business.
Subsequent to quarter-end, the company entered a 36‑month enterprise infrastructure contract with an approximate $260 million aggregate value to deliver a 2,304‑GPU NVIDIA cluster, signaling a significant potential future revenue source alongside its concentrated ATH exposure.
Predictive Oncology Inc. (POAI) filed its Q3 2025 report, showing a sharp net loss as the company repositioned its strategy and balance sheet. For the quarter ended September 30, revenue was $3,618 and operating loss was $3.28 million. A non-cash loss on derivative instruments of $74,366,000 drove a quarterly net loss of $77,651,843. The derivative relates to a cryptocurrency-linked private placement agreement recorded at fair value.
As of September 30, cash and cash equivalents were $181,667, total assets were $3.14 million, and stockholders’ deficit was $(77.43) million, reflecting a recorded derivative liability of $74,366,000. After quarter-end, on October 7, 2025, the company closed two private placements for approximately $50.8 million in aggregate cash gross proceeds, and believes its working capital will fund operations for at least 12 months. POAI completed a 1‑for‑15 reverse stock split effective September 30, 2025, and subsequently regained compliance with Nasdaq’s minimum bid price rule. As of November 10, 2025, there were 3,393,516 common shares outstanding.
Predictive Oncology applies AI and a proprietary biobank of 150,000+ tumor samples to support oncology drug discovery and now operates as a single segment focused on AI-driven cancer-therapy development after reclassifying its Birmingham and Eagan businesses to discontinued operations.
The company reported total assets of $3.44M and total liabilities of $5.09M as of June 30, 2025, producing a stockholders' deficit of $(1.65M). Cash and cash equivalents were $506,078. For the six months ended June 30, 2025 the company recorded revenue of $112,992, a net loss of $4.51M (continuing operations loss of $4.26M), and net cash used in continuing operating activities of $4.28M. The company sold its Eagan assets for $625,000 (plus assumed liabilities) and closed related discontinued operations.
Management discloses substantial doubt about the company’s ability to continue as a going concern without additional financing. Nasdaq notified the company of noncompliance but a Hearings Panel granted an extension through December 8, 2025. Subsequent events include a standby equity purchase agreement providing the right to sell up to $10.0M of common stock subject to conditions and a proposed 1-for-15 reverse stock split subject to stockholder approval.